28
Participants
Start Date
May 20, 2024
Primary Completion Date
April 16, 2025
Study Completion Date
March 19, 2027
TAK-853
TAK-853 intravenous injection
Aichi Cancer Center, Nagoya
Jikei University Kashiwa Hospital, Kashiwa
National Cancer Center Hospital East, Kashiwa
Shikoku Cancer Center, Matsuyama
Kurume University Hospital, Kurume
Hokkaido University Hospital, Sapporo
Sapporo Medical University Hospital, Sapporo
Hyogo Cancer Center, Akashi
Iwate Medical University Hospital, Shiwa-gun
Tohoku University Hospital, Sendai
Saitama Medical University International Medical Center, Hidaka
Shizuoka Cancer Center, Nakatogari
National Cancer Center Hospital, Chuo-ku
Cancer Institute Hospital of JFCR, Koto-ku
The Jikei University Hospital, Minato-ku
Keio University Hospital, Shinjuku-ku
Chiba University Hospital, Chiba
Kyoto University Hospital, Kyoto
Okayama University Hospital, Okayama
Osaka International Cancer Institute, Osaka
Lead Sponsor
Takeda
INDUSTRY